GeoVax Labs, Inc. Chairman and CEO David Dodd will present a company overview and host investor meetings during the H.C. Wainwright 27th Annual Global Investment Conference in New York City. The presentation will focus on recent progress and upcoming milestones across the company's pipeline of vaccines and immunotherapies for infectious diseases and cancer.
The company's GEO-MVA program, a next-generation MVA-based Mpox/smallpox vaccine, recently received favorable Scientific Advice from the European Medicines Agency. This regulatory guidance positions the vaccine to support global preparedness and stockpile strategies, potentially accelerating its development path by omitting Phase 1 and Phase 2 trials and moving directly to Phase 3 clinical evaluation.
GeoVax's COVID-19 vaccine candidate, GEO-CM04S1, is currently being evaluated in three Phase 2 clinical trials targeting various patient populations. The vaccine is being studied as a primary vaccine for immunocompromised patients, including those with hematologic cancers, and as a booster vaccine for patients with chronic lymphocytic leukemia and healthy adults who previously received mRNA vaccines. This addresses critical gaps in protection for vulnerable populations where current authorized vaccines have shown limitations.
The company's oncology program features Gedeptin®, a gene-directed enzyme prodrug therapy for solid tumors, with an upcoming Phase 2 trial focused on head and neck cancer. This therapy recently completed a multicenter Phase 1/2 clinical trial for advanced head and neck cancers, representing an innovative approach to cancer treatment.
GeoVax will also highlight how its MVA platform and U.S.-based continuous cell line manufacturing capabilities position the company to address critical gaps in vaccine supply diversification, pandemic readiness, and biosecurity. The company maintains a strong intellectual property portfolio with worldwide rights for its technologies and products. A webcast of the presentation will be available at https://journey.ct.events/view/40d09ded-caa5-44ff-baf7-10795e9d5386 beginning at 7:00 am ET on September 8, 2025.
